From the above, it can be seen that the FAK/paxillin signaling pathway is involved in several tumor-promoting pathways, so reducing FAK signaling by inhibiting FAK-paxillin interaction is considered a potential tumor therapy strategy. The gene discussed is PTK2; the disease is neoplasm.